Compare SBI & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBI | CPIX |
|---|---|---|
| Founded | 1992 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.9M | 92.3M |
| IPO Year | N/A | 2007 |
| Metric | SBI | CPIX |
|---|---|---|
| Price | $7.67 | $7.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 60.8K | ★ 142.4K |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 4.52% | N/A |
| EPS Growth | N/A | ★ 58.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $42,010,949.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.75 |
| 52 Week Low | $7.51 | $1.85 |
| 52 Week High | $8.01 | $8.42 |
| Indicator | SBI | CPIX |
|---|---|---|
| Relative Strength Index (RSI) | 35.66 | 58.81 |
| Support Level | $7.58 | $5.59 |
| Resistance Level | $7.90 | $8.09 |
| Average True Range (ATR) | 0.08 | 0.93 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 29.41 | 75.67 |
Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes. Under normal market conditions, the Fund will invest at least 80% of its total assets in municipal obligations. In addition, under normal market conditions, the Fund will invest at least 80% of its total assets in debt securities that are, at the time of investment, rated investment grade by a nationally recognized statistical rating organization or, if unrated, of equivalent quality as determined by the investment manager.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.